The U.S. Food and Drug Administration on Wednesday warned about the risk of a rare but serious allergic reaction with the use ...

The U.S. Food and Drug Administration on Wednesday warned about the risk of a rare but serious allergic reaction with the use ...

A promising new treatment accelerates myelin repair, potentially restoring vision and improving brain function in people with ...

Teva Pharmaceutical’s Copaxone was approved by the FDA in 1996 to treat relapsing forms of MS, an autoimmune disorder that ...

The FDA issued a boxed warning for anaphylaxis risk linked to Glatiramer acetate and Glatopa, used in MS treatment.

From 1996-2024, 82 cases of anaphylaxis associated with glatiramer acetate were reported to the FDA Adverse Event Reporting ...

The FDA is adding a new boxed warning to include information that anaphylaxis can occur at any time, from as early as after ...

Patients should stop taking glatiramer acetate and seek immediate medical attention by going to an emergency room or calling ...

After years of legal wrangling surrounding Teva’s Copaxone, the latest hit to the lucrative multiple sclerosis drug comes in ...

Researchers at the University of Colorado Anschutz Medical Campus have found a promising drug candidate that could help ...